YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
Zhi LiuZijian TaoQing ZhangSong WanFenglin ZhangYan ZhangGuanyu WuJian-Dong WangPublished in: Cancer chemotherapy and pharmacology (2018)
Our preliminary observations suggest that the EphA2-targeted MSN delivery system may provide a strategy for enhancing delivery of therapeutic agents to breast cancer cells expressing EphA2, and potentially reduce toxicity while enhancing therapeutic efficacy.